Abstract Number: 0283 • ACR Convergence 2021
Cardiovascular Risk Management in Patients with Rheumatoid Arthritis: A Single-centered Cross-sectional Study
Background/Purpose: Cardiovascular (CV) disease is the leading cause of death in patients with rheumatoid arthritis (RA) and is estimated to be responsible for 29%-32% of…Abstract Number: 1366 • ACR Convergence 2021
The Use of Lipid-Lowering Agents in Systemic Sclerosis: Is There a Relationship with Prevalence of Digital Ulcers and Overall Survival?
Background/Purpose: Digital ulcers (DU) are common in systemic sclerosis (SSc). Vasodilator therapies have limited benefit in prevention and promoting healing. Lipid-lowering agents (LLAs) such as…Abstract Number: 445 • 2019 ACR/ARP Annual Meeting
What Is the Effect of Statins on the Risk of Rheumatoid Arthritis? Results of a Systematic Review and Meta-Analysis
Background/Purpose: The anti-inflammatory and immune-modulating effects of statins suggest that these drugs may influence the risk of developing autoimmune diseases, such as rheumatoid arthritis (RA). …Abstract Number: 955 • 2019 ACR/ARP Annual Meeting
Adherence to Statin Therapy in Rheumatoid Arthritis Patients: A Population-Based Cohort Study
Background/Purpose: Cardiovascular diseases (CVD) are increased in RA and lead to premature mortality. Statins are effective at preventing incidence of, and mortality from, CVD; yet,…
ACR Meeting Abstracts